FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake
The list price of the drug, known chemically as erdafitinib, will range between $10,080 to $22,680 for a 28-day supply, depending of the dose, J&J said. The drug is approved for use in patients whose cancer has progressed during or after chemotherapy and have specific genetic alterations known as FGFR3 or FGFR2. Patients will be selected for therapy with Balversa using an FDA-approved companion diagnostic device that will identify the genetic mutations, the agency said.
“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” Richard Pazdur, head of the FDA’s oncology products division, said in a statement.
You mean the same company that got sued because of their cancer causing product? 🤔
J&J Win Was there a fight? 87 patient trial. Cost-between $10,080 to $22,680 per month. Third had tumour shrinkage in 5.4 mths. Not a cure. COMMON SIDE EFFECTS of drug, mouth sores, fatigue, SERIOUS EYE problems, including inflamed eyes. FDA approved? Future law suit?
Right on !
So they are making a drug to cause bladder cancer? Couldn't they just make more baby powder?
After they’ve been sued for causing cancer ?
This is a great mile stone in the right against cancer. Next question is , what modalities can be put to make it more accessible to all (UHC), while give due respect and reward to the effort behind the Innovation? JNJCares , AtMIndex WHO melindagates
That's the company behind the cancerous cells in their talcum powder right ?
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: washingtonpost - 🏆 95. / 72 Read more »
Source: WSJ - 🏆 98. / 63 Read more »